Cephalalgia : an international journal of headache最新文献

{"title":"Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.","authors":"E Anne MacGregor,&nbsp;Mika Komori,&nbsp;John Henry Krege,&nbsp;Simin Baygani,&nbsp;Maurice Vincent,&nbsp;Jelena Pavlovic,&nbsp;Hisaka Igarashi","doi":"10.1177/03331024221118929","DOIUrl":"https://doi.org/10.1177/03331024221118929","url":null,"abstract":"<p><strong>Background: </strong>Perimenstrual migraine attacks in women with menstrual migraine is difficult to treat. This post-hoc analysis evaluated the efficacy of lasmiditan, a high affinity and selective 5-HT_1F receptor agonist, for perimenstrual attacks.</p><p><strong>Methods: </strong>Patients from two randomized, double-blind, placebo-controlled clinical trials (MONONOFU and CENTURION) were instructed to treat an attack with a single dose of study medication within four hours of pain onset. After dosing, the proportion of patients who achieved freedom from migraine-related head pain, most bothersome symptom, and disability was reported at baseline up to 48 hours after dose and pooled data were evaluated.</p><p><strong>Results: </strong>A total of 303 patients (MONONOFU N = 78; CENTURION N = 225) treated perimenstrual migraine attacks with lasmiditan 50 mg (N = 24), 100 mg (N = 90), 200 mg (N = 110), and placebo (N = 79). More patients achieved migraine-related head pain freedom with lasmiditan 200 mg versus placebo at all time points assessed. At 2 hours, 33.6% of patients in the 200-mg group (p < 0.001), and 16.7% of patients in the 100-mg (p = 0.11) and 50-mg (p = 0.19) groups were pain free, compared with 7.6% in the placebo group.</p><p><strong>Conclusions: </strong>Lasmiditan treatment of perimenstrual migraine attacks was associated with freedom from migraine-related head pain at two hours, early onset of efficacy, and sustained efficacy.<b>Clinical Trial registration:</b> NCT03962738 and NCT03670810.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1467-1475"},"PeriodicalIF":4.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ab/1a/10.1177_03331024221118929.PMC9693902.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40423168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotyping non-idiopathic pseudotumor cerebri syndrome - A prospective cohort study.","authors":"Katrine Svart,&nbsp;Rigmor Højland Jensen,&nbsp;Lisbeth Høgedal,&nbsp;Vlasta Vukovic-Cvetkovic,&nbsp;Dagmar Beier,&nbsp;Johanne Juhl Korsbæk","doi":"10.1177/03331024221120073","DOIUrl":"https://doi.org/10.1177/03331024221120073","url":null,"abstract":"<p><strong>Objective: </strong>To identify the most frequent causes of secondary pseudotumor cerebri syndrome and compare phenotype, clinical presentation, and symptoms of secondary pseudotumor cerebri syndrome to the primary form of pseudotumor cerebri syndrome, idiopathic intracranial hypertension.</p><p><strong>Methods: </strong>The study was a prospective cohort study including patients with new-onset pseudotumor cerebri syndrome. Diagnostic work up was standardized. Patients were diagnosed with secondary pseudotumor cerebri syndrome or idiopathic intracranial hypertension according to the revised Friedman criteria. Secondary pseudotumor cerebri syndrome patients were categorized into five causes: medication, systemic causes, sleep apnea, cerebrovascular causes, and several competing causes. Phenotype, clinical presentation, symptoms and neuroimaging were compared between groups.</p><p><strong>Results: </strong>Out of 278 cases, 28 secondary pseudotumor cerebri syndrome and 120 idiopathic intracranial hypertension patients were included. The most frequent causes of secondary pseudotumor cerebri syndrome were medication (n  =  8, 28.6%) and systemic causes (n = 8, 28.6%), followed by sleep apnea (n = 5, 17.9%), cerebrovascular causes (n = 4, 14.3%) and several competing causes (n = 3, 10.7%). Secondary pseudotumor cerebri syndrome and idiopathic intracranial hypertension patients were phenotypically alike and predominately female, premenopausal, and obese. Symptoms and objective findings at disease onset were similar between groups.</p><p><strong>Conclusion: </strong>Secondary pseudotumor cerebri syndrome should be considered in all patients with suspected pseudotumor cerebri syndrome as secondary pseudotumor cerebri syndrome and idiopathic intracranial hypertension patients are phenotypically and clinically alike. A thorough diagnostic workup is needed as treatment of idiopathic intracranial hypertension and secondary pseudotumor cerebri syndrome is markedly different.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1510-1520"},"PeriodicalIF":4.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40708178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-related differences in cluster headache: A hospital-based study in Taiwan.","authors":"Yi-Chia Liaw,&nbsp;Yen-Feng Wang,&nbsp;Wei-Ta Chen,&nbsp;Shih-Pin Chen,&nbsp;Jr-Wei Wu,&nbsp;Shu-Ting Chen,&nbsp;Kuan-Lin Lai,&nbsp;Jong-Ling Fuh,&nbsp;Shuu-Jiun Wang","doi":"10.1177/03331024221120054","DOIUrl":"https://doi.org/10.1177/03331024221120054","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the clinical profiles between male and female cluster headache patients from a large cohort.</p><p><strong>Methods: </strong>This hospital-based study enrolled patients diagnosed with cluster headache between 1997 to 2021. Participants completed structured questionnaires collecting information on demographics, clinical profiles, and quality of life. Treatment regimens and effectiveness were determined through medical chart review. All variables were compared between the sexes.</p><p><strong>Results: </strong>In total, 798 patients (M/F:659/139) were enrolled. The male-to-female ratio was 4.7:1 for the full study period, but it declined from 5.2:1 to 4.3:1 for patients enrolled before and after 2010, respectively. The frequencies of chronic cluster headache (M:1.2%, F:1.4%) and aura (M:0.3%, F:0.7%) were low but similar between the sexes. Most headache features showed no difference between men and women. Female patients had significantly longer attack duration, shorter inter-bout duration, higher frequencies for eyelid edema, nausea and vomiting and lower frequencies for conjunctival injection and pacing. Sex difference did not influence headache-associated disability, anxiety, or depression, but poor sleep quality was significantly more common in women. Among menstruating women, 22/122 (18.0%) reported worsening headaches during menses. The effectiveness of treatment was similar between the sexes.</p><p><strong>Conclusions: </strong>Despite a decline of male-to-female ratio in the past two decades, most clinical profiles were similar between the sexes.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1532-1542"},"PeriodicalIF":4.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40439506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Galcanezumab modulates Capsaicin-induced C-fiber reactivity.","authors":"Hauke Basedau,&nbsp;Thalea Oppermann,&nbsp;Elisa Gundelwein Silva,&nbsp;Kuan-Po Peng,&nbsp;Arne May","doi":"10.1177/03331024221112906","DOIUrl":"https://doi.org/10.1177/03331024221112906","url":null,"abstract":"<p><strong>Background: </strong>The vasodilatory calcitonin-gene related peptide (CGRP) is understood as pivotal mediator in migraine pathophysiology. Blocking CGRP with small molecules or monoclonal antibodies (CGRP-mAb) reduces migraine frequency. However, prescription of CGRP-mAbs is still regulated and possible predictive measures of therapeutic success would be useful.</p><p><strong>Methods: </strong>Using standardized capsaicin-induced dermal blood flow model, 29 migraine patients underwent a laser speckle imaging measurement before and after administration of galcanezumab. At both sessions dermal blood flow before and after capsaicin stimulation as well as flare size were analyzed over all three trigeminal branches and the volar forearm for extracranial control. Long-term measures were repeated in 14 patients after continuous treatment ranging from 6 to 12 months.</p><p><strong>Results: </strong>Resting dermal blood flow remained unchanged after administration of galcanezumab. Capsaicin-induced dermal blood flow decreased significantly after CGRP-mAb in all tested areas compared to baseline and this was consistent even after 12 months of treatment. However, following galcanezumab administration, the flare size decreased only in the three trigeminal dermatomes, not the arm and was therefore specific for the trigemino-vascular system. None of these two markers distinguished between responders and non-responders.</p><p><strong>Conclusion: </strong>CGRP-mAb changed blood flow response to capsaicin stimulation profoundly and this effect did not change over a 12-month application. Neither capsaicin-induced flare nor dermal blood flow can be used as a predictor for treatment efficacy. These data suggest that the mechanism of headache development in migraine is not entirely CGRP-mediated.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1331-1338"},"PeriodicalIF":4.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/04/10.1177_03331024221112906.PMC9638712.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40477190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccination-triggered cluster headache episodes with frequent attacks.","authors":"Roemer B Brandt,&nbsp;Rosa-Lin H Ouwehand,&nbsp;Michel D Ferrari,&nbsp;Joost Haan,&nbsp;Rolf Fronczek","doi":"10.1177/03331024221113207","DOIUrl":"https://doi.org/10.1177/03331024221113207","url":null,"abstract":"<p><strong>Background: </strong>The pathophysiology of cluster headache and how cluster episodes are triggered, are still poorly understood. Recurrent inflammation of the trigeminovascular system has been hypothesized. It was noted that some long-term attack-free cluster headache patients suddenly developed a new cluster episode shortly after COVID-19 vaccination.</p><p><strong>Methods: </strong>Cases are described from patients with cluster headache who reported a new cluster episode within days after COVID-19 vaccination. All cases were seen in a tertiary university referral center and a general hospital in the Netherlands between March 2021 and December 2021, when the first COVID-19 vaccinations were carried out in The Netherlands. Clinical characteristics of the previous and new cluster episodes, and time between the onset of a new cluster episode and a previous COVID-19 vaccination were reported.</p><p><strong>Results: </strong>We report seven patients with cluster headache, who had been attack-free for a long time, in whom a new cluster episode occurred within a few days after a COVID-19 vaccination.</p><p><strong>Interpretation: </strong>COVID-19 vaccinations may trigger new cluster episodes in patients with cluster headache, possibly by activating a pro-inflammatory state of the trigeminocervical complex. COVID-19 vaccinations may also exacerbate other neuroinflammatory conditions. .</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1420-1424"},"PeriodicalIF":4.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40592255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personal view: Modelling pain mechanisms of migraine without aura.","authors":"Jes Olesen","doi":"10.1177/03331024221111529","DOIUrl":"https://doi.org/10.1177/03331024221111529","url":null,"abstract":"<p><strong>Introduction: </strong>This review aims to model migraine nociception.</p><p><strong>Methods: </strong>Personal experience and litterature.</p><p><strong>Results: </strong>Genetic and environmental factors in combination decide whether a person suffers from migraine. Endogenous and/or exogenous factors precipitate the individual attacks. Nociception takes place around blood vessels. There is a growing understanding of the molecular pathophysiological mechanisms of migraine from human provocation studies. Rodent models of migraine are necessary to understand the complex interrelation between the many putatively involved molecules and tissues but their relevance for human migraine is uncertain. The crucial element in migraine nociception is a unit consisting of endothelial cells, vascular smooth muscle cells, perivascular nerve fibers (trigeminal, parasympathetic and sympathetic) and mast cells. Attacks may start outside the brain by humoral or neurogenic activity releasing nociceptive substances around blood vessels. They may also (perhaps more often) start by the brain generating efferent activity in autonomic and somatic nerves.</p><p><strong>Conclusion: </strong>Human and rodent studies can quickly uncover the \"mystery of migraine\".</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1425-1435"},"PeriodicalIF":4.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40477189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of certain TRP channels and voltage-gated KCNQ/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system.","authors":"Arzu Citak,&nbsp;Erkan Kilinc,&nbsp;Ibrahim Ethem Torun,&nbsp;Seyit Ankarali,&nbsp;Yasar Dagistan,&nbsp;Hamit Yoldas","doi":"10.1177/03331024221114773","DOIUrl":"https://doi.org/10.1177/03331024221114773","url":null,"abstract":"<p><strong>Background: </strong>Calcitonin gene-related peptide release in trigeminovascular system is a pivotal component of neurogenic inflammation underlying migraine pathophysiology. Transient receptor potential channels and voltage-gated KCNQ/Kv7 potassium channels expressed throughout trigeminovascular system are important targets for modulation of calcitonin gene-related peptide release. We investigated the effects of certain transient receptor potential (TRP) channels the vanilloid 1 and 4 (TRPV1 and TRPV4), the ankyrin 1 (TRPA1), and metastatin type 8 (TRPM8), and voltage-gated potassium channel (Kv7) opener retigabine on calcitonin gene-related peptide release from peripheral (dura mater and trigeminal ganglion) and central (trigeminal nucleus caudalis) trigeminal components of rats.</p><p><strong>Methods: </strong>The experiments were carried out using well-established in-vitro preparations (hemiskull, trigeminal ganglion and trigeminal nucleus caudalis) from male Wistar rats. Agonists and antagonists of TRPV1, TRPV4, TRPA1 and TRPM8 channels, and also retigabine were tested on the in-vitro release of calcitonin gene-related peptide. Calcitonin gene-related peptide concentrations were measured using enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Agonists of these transient receptor potential channels induced calcitonin gene-related peptide release from hemiskull, trigeminal ganglion and trigeminal nucleus caudalis, respectively. The transient receptor potential channels-induced calcitonin gene-related peptide releases were blocked by their specific antagonists and reduced by retigabine. Retigabine also decreased basal calcitonin gene-related peptide releases in all preparations.</p><p><strong>Conclusion: </strong>Our findings suggest that favorable antagonists of these transient receptor potential channels, or Kv7 channel opener retigabine may be effective in migraine therapy by inhibiting neurogenic inflammation that requires calcitonin gene-related peptide release.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1375-1386"},"PeriodicalIF":4.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40622583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual snow: A systematic review and a case series.","authors":"Stefanos N Sampatakakis,&nbsp;Loukas Lymperopoulos,&nbsp;Theodoros Mavridis,&nbsp;Georgios Karagiorgis,&nbsp;Constantinos Papadopoulos,&nbsp;Christina I Deligianni,&nbsp;Dimos D Mitsikostas","doi":"10.1177/03331024221118917","DOIUrl":"https://doi.org/10.1177/03331024221118917","url":null,"abstract":"<p><strong>Background: </strong>Visual Snow Syndrome is a recently recognized neurological condition presenting, continuous, tiny dots across the entire visual field, accompanied by nyctalopia, photophobia and palinopsia that persist for months. It may be part of migraine aura spectrum, yet its definition is still questionable. Diagnostic criteria for Visual Snow Syndrome are included in the supplemental material of ICHD-3. We aimed to summarize recent data to improve the understanding of Visual Snow Syndrome.</p><p><strong>Methods: </strong>After presenting four new cases, we conducted a PRISMA systematic search in PubMed/MEDLINE and Embase databases using the keyword \"visual snow\" with specific inclusion and exclusion criteria.</p><p><strong>Results: </strong>From the 855 articles identified 30 were included for the qualitative analysis. These reports covered five aspects related to Visual Snow Syndrome: epidemiology, clinical features, comorbidities, pathophysiology, and treatment. We found limited data concerning Visual Snow Syndrome's epidemiology (one study). Clinical presentation (22 articles) and the comorbidities (migraine with aura and tinnitus most often, five reports) are described in detail. The pathophysiology of Visual Snow Syndrome is only approached with hypotheses, but several neuroimaging studies have been identified (seven articles). Treatment is based on single case reports only.</p><p><strong>Conclusion: </strong>Data for Visual Snow Syndrome are few and not strong enough to support Visual Snow Syndrome as a medical identity. Further investigation is needed.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1409-1419"},"PeriodicalIF":4.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40614543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.","authors":"Luigi Francesco Iannone,&nbsp;Francesco De Cesaris,&nbsp;Anita Ferrari,&nbsp;Silvia Benemei,&nbsp;Davide Fattori,&nbsp;Alberto Chiarugi","doi":"10.1177/03331024221111526","DOIUrl":"https://doi.org/10.1177/03331024221111526","url":null,"abstract":"<p><strong>Background: </strong>Clinical trials and observational studies with anti-calcitonin gene-related peptide antibodies poorly investigated their impact on migraine prodromal and accompanying symptoms. This information might help deciphering the biologics' pharmacodynamic and provide hints on migraine pathogenesis. Herein, we report the effects of erenumab, fremanezumab and galcanezumab on attack prodromal and accompanying symptoms and on neurological and psychiatric traits. .</p><p><strong>Methods: </strong>An explorative, prospective, questionnaire-based study was completed by a cohort (n = 80) of patients with chronic migraine patients presenting a sustained reduction of ≥50% of Migraine Disability Assessment Score and ≥30% of monthly migraine days three months after anti-calcitonin gene-related peptide antibodies treatment.</p><p><strong>Results: </strong>The majority of patients experienced a complete prevention of migraine symptoms without evidence of initial onset followed by attack abortion. Few patients reported the recurrence of prodromal (from 10% to 12.5%) or accompanying (from 1.3% to 8.8%) symptoms without headache. All patients with migraine with aura reported a decrease of aura incidence. Sleep changes (51.2%), increase in appetite (20.0%) and weight (18.8%) as well as a reduction in stress (45.0%), anxiety (26.3%), and panic attacks (15%) were also reported.</p><p><strong>Conclusion: </strong>Anti-calcitonin gene-related peptide antibodies seems to significantly impact brain functions of migraineurs, preventing not only migraine headache but also its anticipatory and accompanying symptoms.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1323-1330"},"PeriodicalIF":4.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40562672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric screen exposure and school related headache disability.","authors":"Raquel Langdon,&nbsp;Alexandra Mandel,&nbsp;Mark Cameron,&nbsp;Emily Pierce,&nbsp;Emily McCracken,&nbsp;Jeffrey Strelzik,&nbsp;William McClintock,&nbsp;James Bost,&nbsp;Marc DiSabella","doi":"10.1177/03331024221113468","DOIUrl":"https://doi.org/10.1177/03331024221113468","url":null,"abstract":"<p><strong>Background and objectives: </strong>Prolonged screen exposure is often cited as a trigger for pediatric headache. We present initial findings evaluating the association between adolescent screen use type, duration, and school disability.</p><p><strong>Methods: </strong>New patients aged 12-17 years presenting to a headache clinic were screened and surveyed regarding headache characteristics, behavioral habits, school attendance, and screen utilization.</p><p><strong>Results: </strong>99 adolescents (29 M, 70 F) with average age 14.8 years and average headache frequency of 17 days per month completed the survey. Patients missed an average of five full days and three partial days of school due to headaches over the 90 days prior to survey completion.No statistically significant correlation was found between type or duration of screen exposure and monthly headache frequency, school attendance, or school functioning. A small positive association was seen between increasing duration of computer use, total hours screen use, and school absenteeism. While most adolescents reported prolonged screen use (58.6%) and luminosity (64.6%) worsened headaches, no statistical difference was seen in average number of headache days per month.</p><p><strong>Conclusions: </strong>Average monthly headache frequency in an adolescent population was not significantly correlated with type or duration of screen exposure. Further studies are needed to elucidate how screen utilization impacts school related headache disability.</p>","PeriodicalId":195255,"journal":{"name":"Cephalalgia : an international journal of headache","volume":" ","pages":"1349-1358"},"PeriodicalIF":4.9,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40605309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}